stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Return on equity
Sarepta Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −8.05%, up 45.4 percentage points from fiscal 2025 (−53.5%). Over the past ten years it has ranged from −107.2% (fiscal 2022) to 19.7% (fiscal 2024); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of −52.0% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −53.5% | (73.18) |
| FY2024 | 19.7% | 105.86 |
| FY2023 | −86.2% | 21.01 |
| FY2022 | −107.2% | (57.59) |
| FY2021 | −49.6% | 20.58 |
| FY2020 | −70.2% | 7.14 |
| FY2019 | −77.3% | (37.55) |
| FY2018 | −39.7% | (30.74) |
| FY2017 | −9.00% | 92.42 |
| FY2016 | −101.4% | (0.95) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 18.7% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. | −8.05% |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −17.0% |
| TRVI Trevi Therapeutics, Inc. compare | −19.7% |
| VIR Vir Biotechnology, Inc. compare | −21.8% |
| MAZE Maze Therapeutics, Inc. compare | −37.4% |
| REPL Replimune Group, Inc. compare | −115.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)